PT-141 Bremelanotide 10mg Melanocortin Peptide

PT-141

Bremelanotide · Central sexual desire (melanocortin)

99% Purity Sexual Health Neuroactive

PT-141 (Bremelanotide) is a synthetic α-MSH analog that acts on the MC3R and MC4R melanocortin receptors in the central nervous system, activating sexual desire directly from the brain (not through the vascular route like sildenafil). FDA-approved under the name Vyleesi for female hypoactive sexual desire disorder, it is also used off-label in men with erectile dysfunction of non-vascular origin.

Key Benefits

Activates sexual desire in the brain

Effective in men and women

Does not depend on the vascular route

Useful where Viagra/Cialis fail

Rapid effect (30 min–2 h)

Duration of 6–12 hours

Mechanism of Action

As a synthetic α-MSH analog, PT-141 activates the MC3R and MC4R melanocortin receptors in the central nervous system, stimulating sexual desire directly from the brain rather than through the vascular route like sildenafil.

Verify Product Contact

Protocol

Reconstitution & Usage Protocol

Important: Only set the water to cool 3 minutes before reconstituting the peptide. Do not prepare with very cold water, because it may freeze, lose potency or be damaged.

1Reconstitution

Materials: 1 vial of PT-141 10 mg · 1 vial of bacteriostatic water · U-100 insulin syringe · alcohol wipes.

Bring the vial to room temperature for 10–15 minutes.
Disinfect the rubber caps with an alcohol wipe.
Draw up 2 mL of bacteriostatic water (200 IU).
Inject the water slowly down the inner wall of the vial.
Do not shake. Swirl gently until the solution is clear.

Label with the date and refrigerate (2–8 °C). Stable for 28 days.

2Concentration & Dosing

Reconstituting 10 mg in 2 mL → 5 mg/mL = 50 mcg per IU.

Target dose	Units	Volume
500 mcg (low)	10 IU	0.10 mL
1 mg (standard women)	20 IU	0.20 mL
1.75 mg (FDA standard)	35 IU	0.35 mL
2 mg (high men)	40 IU	0.40 mL

Universal formula: IU = (dose in mcg ÷ 50)

3Application

Route

Subcutaneous in the abdomen or thigh.

Frequency

As needed, maximum 8 doses/month. Not daily.

Timing of application: 45 min – 2 h before sexual activity.
Common side effects: mild nausea (first use), facial flushing, transient headache.
Before applying: let the drawn-up dose lose its chill (only the amount to be injected) — hold the syringe in your hand for 2–3 minutes.
After applying: gently massage the area for ~40 seconds to disperse the peptide and improve absorption.

Importante: Solo poner a enfriar el agua 3 minutos antes de reconstituir el péptido. No preparar con agua muy fría, porque se puede congelar, perder efecto o dañarse.

1Reconstitución

Materiales: 1 vial de PT-141 10 mg · 1 vial de agua bacteriostática · jeringa de insulina U-100 · toallitas de alcohol.

Atemperar el vial 10–15 minutos.
Desinfectar las tapas de goma con toallita de alcohol.
Cargar 2 mL de agua bacteriostática (200 UI).
Inyectar el agua lentamente por la pared interior del vial.
No agitar. Girar suavemente hasta solución transparente.

Etiquetar con fecha y refrigerar (2–8 °C). Estable 28 días.

2Concentración y dosis

Reconstituyendo 10 mg en 2 mL → 5 mg/mL = 50 mcg por UI.

Dosis objetivo	Unidades	Volumen
500 mcg (baja)	10 UI	0,10 mL
1 mg (estándar mujeres)	20 UI	0,20 mL
1,75 mg (estándar FDA)	35 UI	0,35 mL
2 mg (alta hombres)	40 UI	0,40 mL

Fórmula universal: UI = (dosis en mcg ÷ 50)

3Aplicación

Vía

Subcutánea en abdomen o muslo.

Frecuencia

Según necesidad, máximo 8 dosis/mes. No diario.

Tiempo de aplicación: 45 min – 2 h antes de la actividad sexual.
Efectos secundarios comunes: náuseas leves (primer uso), rubor facial, cefalea transitoria.
Antes de aplicar: dejar que la dosis cargada pierda el frío (solo la cantidad a inyectar) — sostener la jeringa en la mano 2–3 minutos.
Después de aplicar: masaje suave en la zona durante ~40 segundos para dispersar el péptido y mejorar absorción.

Important : Ne mettre l'eau à refroidir que 3 minutes avant de reconstituer le peptide. Ne pas préparer avec une eau très froide, car elle peut geler, perdre de son effet ou s'abîmer.

1Reconstitution

Matériel : 1 flacon de PT-141 10 mg · 1 flacon d'eau bactériostatique · seringue à insuline U-100 · lingettes alcoolisées.

Laisser le flacon revenir à température 10–15 minutes.
Désinfecter les bouchons en caoutchouc avec une lingette alcoolisée.
Prélever 2 mL d'eau bactériostatique (200 UI).
Injecter l'eau lentement le long de la paroi intérieure du flacon.
Ne pas agiter. Tourner doucement jusqu'à obtenir une solution transparente.

Étiqueter avec la date et réfrigérer (2–8 °C). Stable 28 jours.

2Concentration et dosage

En reconstituant 10 mg dans 2 mL → 5 mg/mL = 50 mcg par UI.

Dose cible	Unités	Volume
500 mcg (faible)	10 UI	0,10 mL
1 mg (standard femmes)	20 UI	0,20 mL
1,75 mg (standard FDA)	35 UI	0,35 mL
2 mg (élevée hommes)	40 UI	0,40 mL

Formule universelle : UI = (dose en mcg ÷ 50)

3Application

Voie

Sous-cutanée dans l'abdomen ou la cuisse.

Fréquence

Selon les besoins, maximum 8 doses/mois. Pas quotidien.

Moment d'application : 45 min – 2 h avant l'activité sexuelle.
Effets secondaires courants : nausées légères (première utilisation), bouffées de chaleur au visage, céphalée transitoire.
Avant d'appliquer : laisser la dose prélevée perdre sa fraîcheur (seulement la quantité à injecter) — tenir la seringue dans la main 2–3 minutes.
Après l'application : masser doucement la zone pendant ~40 secondes pour disperser le peptide et améliorer l'absorption.

Open dosage calculator →

Research Highlights

PT-141 is studied as a melanocortin MC3R/MC4R agonist acting on central nervous system pathways of sexual desire rather than peripheral vascular flow.
As the basis for FDA-approved Vyleesi for female hypoactive sexual desire disorder, it is researched for libido and sexual response in both men and women without altering blood pressure.
Research handling reports a rapid onset of 30 minutes to 2 hours after subcutaneous application with an activity window of 6–12 hours.

FAQ

Frequently Asked Questions

What is PT-141 (Bremelanotide) and how does it differ from PDE5 inhibitors?

PT-141 is a synthetic α-MSH analog studied as an MC3R/MC4R melanocortin agonist that acts on central sexual desire pathways in the brain, rather than the peripheral vascular mechanism of PDE5 inhibitors like sildenafil. In research framing this makes it relevant where vascular comparators do not respond and it does not alter blood pressure. Supplied as a lyophilized 10 mg vial for laboratory research use only.

What onset and duration of action are reported for PT-141 in research?

Research handling references a rapid onset between 30 minutes and 2 hours after subcutaneous application, with an observed activity window of roughly 6–12 hours. Because the effect is attributed to central neural signaling rather than peripheral blood flow, the timing differs from vascular comparators.

How is the 10 mg vial reconstituted and dosed in research protocols?

Reconstituting 10 mg in 2 mL of bacteriostatic water gives a 5 mg/mL stock, equal to 50 mcg per IU on a U-100 insulin syringe. The universal formula IU = (dose in mcg ÷ 50) lets you map any target to volume — for example 1.75 mg equals 35 IU or 0.35 mL. Direct the diluent down the vial wall and swirl gently rather than shaking.

How should reconstituted PT-141 be stored and how often is it used?

Once reconstituted, label the vial with the date and refrigerate at 2–8 °C protected from light, where it remains stable for 28 days. Research handling references a maximum of 8 doses per month, not daily use, with subcutaneous handling in the abdomen or thigh. Use very cold water only briefly cooled, as freezing can damage the peptide.

Related Compounds

← Previous

Kisspeptin-10

Melanotan II

← Back to full catalog